

SUPPLEMENTAL MATERIAL

Table S1. Characteristics of HFpEF patients and their age- and sex-matched controls.

	HFpEF (n=20)	Control (n=20)
Age (yrs)	66±7	64±5
Male/female	8/12	7/13
Etiology of HFpEF*		
Ischemic	1	0
Hypertensive/Non-ischemic/Unknown	19	0
Comorbidities*		
Obesity (BMI >28kg/m ²)	4	0
Hypertension	16	0
Type 2 diabetes mellitus	14	2
Atrial fibrillation/flutter	8	0
Systolic blood pressure (mmHg)*	136±29	121±22
Diastolic blood pressure (mmHg)*	80±12	72±9
Heart rate (bpm)	76±3	72±3
QRS duration (ms)*	104±20	95±15
NYHA functional class*		
I	4	18
II	10	2
III	6	0
IV	0	0
Echocardiography:		
LVEF (%)	55.6±5.7	59.2±7.2
IVS (mm)*	12.2±3.1	10.1±1.9
PW (mm)*	11.6±2.8	9.8±1.6
LVEDD (mm)	46.1±5.8	47.2±6.3
LVESD (mm)	30.1±6.9	30.6±5.5
LV mass (g)*	186±45	156±35
PA pressure (mmHg)*	42±11	26±8.5
Laboratory values		
Cardiac TnT (mg/mL)	0.03±0.03	0.02±0.03
BNP (pg/mL)*	260±51	30±5
Creatinine (mg/dL)*	1.47±0.9	0.89±0.5
MDRD eGFR (mL/min/1.73 m ²)*	49±12	74±14
Sodium (mmol/L)	139±3.8	138±4.1
Hemoglobin (g/dL)	11.8±1.9	12.6±1.8
Glucose (mg/dL)*	146±38	91±19

LVEF: Left Ventricular Ejection Fraction; LV: Left ventricular; IVS: Intraventricular septal thickness; LVEDD: LV End Diastolic Diameter; LVESD: LV End Systolic Diameter; PW: Posterior Wall Thickness; NYHA, New York Heart Association; MDRD eGFR, glomerular filtration rate by Modification of Diet in Renal Disease equation; BNP, brain natriuretic peptide; TnT, troponin T. Grade 1 diastolic dysfunction: impaired relaxation; Grade 2 diastolic dysfunction: pseudonormal filling pattern; Grade 3 diastolic dysfunction: reversible restrictive filling pattern. * $P < 0.05$ HFpEF vs control.

Figure S1. mRNA expression of Anp, Bnp, collagen 1, collagen 3 and IL-10 after HMGB1 inhibition in mice. *P < 0.05 vs. Control; †P < 0.05 vs. HFpEF.




Figure S2. Quantification of levels of cell-free DNA from cultured differentiated neutrophils of indicated treatments.

